bluebird bio, Inc. (0HOH.L)

Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy

The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLOFLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to provide multiple health plans with access to an innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene autotem